The Investigational New Drug Program of the Canadian Cancer Trials Group
Kingston, Ontario
Joined October 2022
- Tweets164
- Following91
- Followers44
- Likes143
Congratulations @Philippe_Bedard on the ESMO-TAT Honorary Award 2025 @CDNCancerTrials
MDICT 2024 recommendations for neoadjuvant early clinical trials now published. Led by ESMO-TAT chairs @lillian_siu @ElenaGarralda @AnastasiosStat2 and MDICT’24 team supported by @myESMO
sciencedirect.com/science/ar…
Dr Helen Mackay presenting our ongoing trial IND.240 #ASCO23 @JEDancey @CDNCancerTrials @CancerResearch @DrPOGaudreau for patients with high grade serous ovarian cancer
(2/3) I also invite you to visit our CCTG IND trial posters at ASCO, including IND.240 (Dr. Helen MacKay):
Time: Jun/5/2023, 1:15 PM CDT Hall A
meetings.asco.org/abstracts-…
@INDProgramCCTG @CDNCancerTrials
#immunotherapy #ovariancancer
Dr Quincy Chu concluding his presentation of IND.227, a collaboration of
@istitutotumori
@IFCTlung
@CDNCancerTrials
Great to have worked again with our long-standing collaborators in Naples - un grande piacere aver collaborato nuovamente con NCI Napoli
IND.227 presented today #ASCO2023 by Dr Chu. Met all endpoints significantly improved survival with a 21% reduction in risk of death. ctg.queensu.ca/cctg_media_re…. @CDNCancerTrials @istitutotumori @AIOMtweet @IFCTlung
“The data presented today demonstrate that the use of pembrolizumab and platinum-pemetrexed chemotherapy extends the lives of patients with unresectable advanced or metastatic pleural mesothelioma,” said Dr Quincy Chu, #CCTG study chair for IND227 #solvingcancertogether
